{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:11:30Z","timestamp":1790964690087,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Southeast Asia"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.lansea.2024.100495","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T10:49:11Z","timestamp":1728989351000},"page":"100495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Deferoxamine, deferasirox, and deferiprone triple iron chelator combination therapy for transfusion-dependent \u03b2-thalassaemia with very high iron overload: a randomised clinical trial"],"prefix":"10.1016","volume":"30","author":[{"given":"Anuja","family":"Premawardhena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakuni","family":"Wanasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chamodi","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muditha Nayana","family":"Wijethilaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.H.M.G.","family":"Rajakaruna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.N.K.K.","family":"Samarasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senani","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachith","family":"Mettananda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10116","key":"10.1016\/j.lansea.2024.100495_bib1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(17)31822-6","article-title":"Thalassaemia","volume":"391","author":"Taher","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.lansea.2024.100495_bib2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.hoc.2017.11.003","article-title":"Molecular basis and genetic modifiers of thalassemia","volume":"32","author":"Mettananda","year":"2018","journal-title":"Hematol Oncol Clin N Am"},{"issue":"1","key":"10.1016\/j.lansea.2024.100495_bib3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12955-019-1207-9","article-title":"Health related quality of life among children with transfusion dependent beta-thalassaemia major and haemoglobin E beta-thalassaemia in Sri Lanka: a case control study","volume":"17","author":"Mettananda","year":"2019","journal-title":"Health Qual Life Outcome"},{"issue":"1","key":"10.1016\/j.lansea.2024.100495_bib4","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1016\/S2214-109X(21)00446-0","article-title":"Survival and complications in patients with haemoglobin E thalassaemia in Sri Lanka: a prospective, longitudinal cohort study","volume":"10","author":"Premawardhena","year":"2022","journal-title":"Lancet Glob Health"},{"issue":"17","key":"10.1016\/j.lansea.2024.100495_bib5","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood-2018-06-818187","article-title":"How I manage medical complications of beta-thalassemia in adults","volume":"132","author":"Taher","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.lansea.2024.100495_bib6","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1182\/blood-2014-10-606491","article-title":"Hepcidin is suppressed by erythropoiesis in hemoglobin E \u03b2-thalassemia and \u03b2-thalassemia trait","volume":"125","author":"Jones","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.lansea.2024.100495_bib7","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.hoc.2014.04.003","article-title":"The pathophysiology of transfusional iron overload","volume":"28","author":"Porter","year":"2014","journal-title":"Hematol Oncol Clin N Am"},{"issue":"8","key":"10.1016\/j.lansea.2024.100495_bib8","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000732","article-title":"2021 Thalassaemia international federation guidelines for the management of transfusion-dependent thalassemia","volume":"6","author":"Farmakis","year":"2022","journal-title":"Hemasphere"},{"issue":"4","key":"10.1016\/j.lansea.2024.100495_bib9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.transci.2019.03.021","article-title":"A\u00a01-year randomized trial of deferasirox alone versus deferasirox and deferoxamine combination for the treatment of iron overload in thalassemia major","volume":"58","author":"Eghbali","year":"2019","journal-title":"Transfus Apher Sci"},{"issue":"2","key":"10.1016\/j.lansea.2024.100495_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-077342","article-title":"Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent \u03b2-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial","volume":"14","author":"Premawardhena","year":"2024","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.lansea.2024.100495_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220852","article-title":"A\u00a0nationwide survey of hospital-based thalassemia patients and standards of care and a preliminary assessment of the national prevention program in Sri Lanka","volume":"14","author":"Premawardhana","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.lansea.2024.100495_bib12","first-page":"239","article-title":"A\u00a0review on iron chelators in treatment of iron overload syndromes","volume":"10","author":"Mobarra","year":"2016","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"issue":"1","key":"10.1016\/j.lansea.2024.100495_bib13","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2020.029","article-title":"Cost-utility analysis of four chelation regimens for \u03b2-thalassemia major: a Chinese perspective","volume":"12","author":"Li","year":"2020","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"9","key":"10.1016\/j.lansea.2024.100495_bib14","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2005-07-2948","article-title":"Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis","volume":"107","author":"Pennell","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.lansea.2024.100495_bib15","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/ejh.12977","article-title":"A\u00a0randomized, controlled study evaluating effects of amlodipine addition to chelators to reduce iron loading in patients with thalassemia major","volume":"99","author":"Eghbali","year":"2017","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.lansea.2024.100495_bib16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1182\/blood-2003-08-2841","article-title":"Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major","volume":"104","author":"Davis","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.lansea.2024.100495_bib17","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1182\/blood-2002-10-3280","article-title":"Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone","volume":"102","author":"Cohen","year":"2003","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.lansea.2024.100495_bib18","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/pbc.24678","article-title":"Distal ulnar changes in children with thalassemia and deferiprone related arthropathy","volume":"60","author":"Sharma","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.lansea.2024.100495_bib19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF02724272","article-title":"Deferiprone, efficacy and safety","volume":"71","author":"Choudhry","year":"2004","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.lansea.2024.100495_bib20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejphar.2015.08.017","article-title":"Current and future treatment strategies for iron overload cardiomyopathy","volume":"765","author":"Wongjaikam","year":"2015","journal-title":"Eur J Pharmacol"}],"container-title":["The Lancet Regional Health - Southeast Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772368224001458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772368224001458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T05:31:23Z","timestamp":1731043883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772368224001458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":20,"alternative-id":["S2772368224001458"],"URL":"https:\/\/doi.org\/10.1016\/j.lansea.2024.100495","relation":{},"ISSN":["2772-3682"],"issn-type":[{"value":"2772-3682","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deferoxamine, deferasirox, and deferiprone triple iron chelator combination therapy for transfusion-dependent \u03b2-thalassaemia with very high iron overload: a randomised clinical trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Southeast Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lansea.2024.100495","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100495"}}